Please login to the form below

Not currently logged in
Email:
Password:

Spanish pharma recovery won't begin until after 2014

Country's pharmaceutical market is yet to hit rock bottom

Spain flag

The Spanish pharmaceutical market has yet to reach its lowest point since the global recession of 2008, according to a new report.

GlobalData said that, although the market will further shrink in value next year, it will begin a slow recovery after 2014, and the analysts highlighted the increase use of biologics as a growth driver.

The research and consulting firm said cancer and rheumatoid arthritis in particular would prove to be an important market catalyst.

“Despite higher list prices, the greater safety and efficacy profiles offered by these treatments are expected to drive up prescription rates, ultimately resulting in pharmaceutical market growth,” the company said.

GlobalData expects the market to fall to $24.6bn in 2014, but said steady growth thereafter should push total sales up to $29.4bn in 2020.

“The Spanish pharmaceutical sector will soon turn a corner, with [its] market value expected to demonstrate steady growth by the end of the decade,” it said.

Another factor behind the country's anticipated market growth is its increasing elderly population, which is expanding at a rate that is expected to give Spain the world's oldest population by 2050, when 50 per cent of its citizens will be at least 55 years old.

The country has already endured years of austerity spending cuts in healthcare, with a direct and significant effect on pharmaceutical revenues.

Last year the Ministry of Health acknowledged its pharma spending had fallen by almost a quarter since 2011, prompting the industry to warn it was close to collapse, in part due to unpaid debts.

Meanwhile, government cuts and privatisation plans have provoked protests by healthcare workers and the general public.

2nd July 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics